Compare Stocks: ZYME, IONS, IMVT, and ALKS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$40.15 -1.7%	$47.77	$27.00 ▼ $55.67	$6.85B	0.31	2.00 million shs	2.09 million shs
IMVT Immunovant	$33.49 +0.6%	$39.62	$15.81 ▼ $45.42	$6.88B	0.81	1.49 million shs	1.23 million shs
IONS Ionis Pharmaceuticals	$45.57 +2.4%	$54.77	$43.01 ▼ $86.74	$7.40B	0.42	4.37 million shs	3.56 million shs
ZYME Zymeworks	$27.12 +2.3%	$26.06	$16.00 ▼ $31.34	$1.88B	1.19	681,563 shs	638,787 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-5.85%	-13.84%	-22.23%	+46.47%
IMVT Immunovant	0.00%	-9.88%	-19.17%	-13.53%	+105.18%
IONS Ionis Pharmaceuticals	0.00%	+0.14%	-27.11%	-44.85%	-30.57%
ZYME Zymeworks	0.00%	-0.19%	-6.19%	+10.04%	+59.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$40.15 -1.7%	$47.77	$27.00 ▼ $55.67	$6.85B	0.31	2.00 million shs	2.09 million shs
IMVT Immunovant	$33.49 +0.6%	$39.62	$15.81 ▼ $45.42	$6.88B	0.81	1.49 million shs	1.23 million shs
IONS Ionis Pharmaceuticals	$45.57 +2.4%	$54.77	$43.01 ▼ $86.74	$7.40B	0.42	4.37 million shs	3.56 million shs
ZYME Zymeworks	$27.12 +2.3%	$26.06	$16.00 ▼ $31.34	$1.88B	1.19	681,563 shs	638,787 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-5.85%	-13.84%	-22.23%	+46.47%
IMVT Immunovant	0.00%	-9.88%	-19.17%	-13.53%	+105.18%
IONS Ionis Pharmaceuticals	0.00%	+0.14%	-27.11%	-44.85%	-30.57%
ZYME Zymeworks	0.00%	-0.19%	-6.19%	+10.04%	+59.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.74	Moderate Buy	$54.47	35.67% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	31.38% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	95.74% Upside
ZYME Zymeworks	2.75	Moderate Buy	$41.00	51.18% Upside

Current Analyst Ratings Breakdown

Latest ZYME, IONS, IMVT, and ALKS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$85.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$50.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$50.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00
9/23/2026	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2026	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$56.00
9/22/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $61.00
9/22/2026	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$76.00 ➝ $70.00
9/21/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	4.56	$1.65 per share	24.40	$11.02 per share	3.64
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
IONS Ionis Pharmaceuticals	$944M	8.02	N/A	N/A	$3.02 per share	15.09
ZYME Zymeworks	$105.96M	18.16	N/A	N/A	$3.59 per share	7.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	105.66	167.29	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	53.18	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest ZYME, IONS, IMVT, and ALKS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
IMVT Immunovant	N/A	7.27	7.27
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
IMVT Immunovant	47.08%
IONS Ionis Pharmaceuticals	93.86%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
IMVT Immunovant	1.90%
IONS Ionis Pharmaceuticals	1.81%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
ZYME Zymeworks	264	70.96 million	47.18 million	N/A

ZYME, IONS, IMVT, and ALKS Headlines

Recent News About These Companies

Zymeworks raises 2026 guidance after closing Theravance acquisition

September 28 at 3:17 PM | streetinsider.com

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

September 28 at 3:17 PM | finance.yahoo.com

Zymeworks Inc. Updates Earnings Guidance for the Year 2026

September 28 at 12:47 PM | marketscreener.comM

Zymeworks Appoints Stuart Knight as Executive Vice President & Chief Information Officer

September 28 at 12:47 PM | marketscreener.comM

Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow

September 28 at 9:01 AM | seekingalpha.com

Zymeworks Issues Updated 2026 Financial Guidance

September 28 at 7:46 AM | rttnews.com

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

September 28 at 6:00 AM | globenewswire.com

Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME

September 28 at 3:19 AM | marketbeat.com

Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger

September 26 at 1:30 PM | kalkinemedia.comK

Vancouver biotech Zymeworks closes US$929M Theravance deal

September 24, 2026 | vancouverisawesome.comV

Zymeworks Completes Acquisition of Theravance Biopharma

September 23, 2026 | globenewswire.com

Head-To-Head Survey: Zymeworks (NASDAQ:ZYME) & Alnylam Pharmaceuticals (NASDAQ:ALNY)

September 23, 2026 | americanbankingnews.com

Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME

September 22, 2026 | marketbeat.com

Zymeworks stock gains on fresh Wolfe Research coverage

September 21, 2026 | ad-hoc-news.deA

Zymeworks stock gains on merger approval and a $41 target

September 20, 2026 | ad-hoc-news.deA

Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts

September 20, 2026 | americanbankingnews.com

Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages

September 20, 2026 | marketbeat.com

Theravance Shareholders Approve Merger with Zymeworks Inc.

September 18, 2026 | tipranks.com

Wolfe Research Begins Coverage on Zymeworks (NASDAQ:ZYME)

September 17, 2026 | marketbeat.com

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME

September 12, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZYME, IONS, IMVT, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

$40.15 -0.70 (-1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$39.83 -0.32 (-0.80%)

As of 07:58 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant NASDAQ:IMVT

$33.49 +0.19 (+0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$33.48 -0.01 (-0.03%)

As of 07:30 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ionis Pharmaceuticals NASDAQ:IONS

$45.57 +1.07 (+2.40%)

Closing price 04:00 PM Eastern

Extended Trading

$45.96 +0.39 (+0.86%)

As of 07:38 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Zymeworks NASDAQ:ZYME

$27.12 +0.60 (+2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$27.78 +0.66 (+2.43%)

As of 07:30 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, IONS, IMVT, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, IONS, IMVT, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, IONS, IMVT, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZYME, IONS, IMVT, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, IONS, IMVT, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, IONS, IMVT, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, IONS, IMVT, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZYME, IONS, IMVT, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools